Healthy
Conditions
Brief summary
This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive up to 3 doses of LY3372689 or placebo. The study will last about 12 weeks, including screening.
Interventions
DRUGLY3372689
Administered orally
DRUGPlacebo
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Overtly healthy male or a female who cannot get pregnant * Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study * Have veins suitable for ease of blood sampling
Exclusion criteria
* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study * Have previously participated or withdrawn from this study * Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure * Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * Have long exposure to sunlight routinely or use tanning beds regularly
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration | Baseline through final follow-up at approximately Week 12 | A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY3372689 | Baseline through to final follow-up at approximately Week 12 | Pharmacokinetics: Cmax of LY3372689 |
| Pharmacokinetics: Time to Maximum Blood Concentration (Tmax) of LY3372689 | Baseline through final follow-up at approximately Week 12 | Pharmacokinetics: Tmax of LY3372689 |
| Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3372689 | Baseline through final follow-up at approximately Week 12 | Pharmacokinetics: AUC of LY3372689 |
Countries
United States
Outcome results
None listed